The latest episode of Denatured features a discussion with Hans Eriksson, chief medical officer at FundaMental Pharma, and Steve Levine, chief patient officer at Compass Pathways, focusing on the persistent challenges of treatment-resistant depression and potential new therapies. The conversation was released on Aug. 6.
Jennifer C. Smith-Parker, director of insights at BioSpace, hosts the episode where Eriksson and Levine examine why treatment-resistant depression remains difficult to address despite advances in mental health care. The guests explore emerging approaches such as rapid-acting antidepressants and psychedelic therapy that could potentially change how this condition is treated.
Listeners can access the episode across several platforms, including Spotify, Apple Podcasts, Amazon Music, iHeart Radio, and YouTube.
During the discussion, both Eriksson and Levine share their perspectives based on their roles in pharmaceutical development and patient advocacy. They discuss current research trends as well as ongoing efforts to develop more effective treatments for individuals who do not respond to conventional therapies.
A disclaimer notes that "the views expressed in this discussion by guests are their own and do not represent those of their organizations."
